



THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION. If you are in any doubt about the contents of this document or the action you should take, you are recommended to seek your own personal financial advice immediately from your stockbroker, bank manager, solicitor, accountant or independent financial adviser duly authorised under the Financial Services and Markets Act 2000 (as amended), if you are resident in the United Kingdom or, if not, from another appropriately authorised independent financial adviser.

If you have sold or otherwise transferred all of your ordinary shares in the capital of hVIVO plc (“**Offeree**” or the “**Company**”) please send this document, as soon as possible, to the purchaser or transferee, or to the stockbroker, bank or other agent through whom the sale or transfer was effected, for transmission to the purchaser or transferee. However, this document should not be forwarded or transmitted in or into or from the United States, Canada, Australia or Japan or any other jurisdiction if to do so would constitute a violation of the relevant laws of such jurisdiction. The distribution of this document in jurisdictions other than the United Kingdom may be restricted by law and therefore persons into whose possession this document comes should inform themselves about and observe such restrictions. Any failure to comply with these restrictions may constitute a violation of the securities laws of any such jurisdiction.

hVIVO plc

(Incorporated in England and Wales under the Companies Act 2006 with registered number 08008725)

Directors:

Dr Trevor Phillips
Dr Trevor Nicholls
Dr Mark Warne
James Winschel

Registered Office:

Queen Mary BioEnterprises Innovation Centre
42 New Road
London
E1 2AX

9 December 2019

To all hVIVO plc Shareholders and persons with information rights


Recommended offer for hVIVO plc (the “Company”) by Open Orphan plc

Dear hVIVO plc Shareholder,

In accordance with Rule 2.11 of the City Code on Takeovers and Mergers (the “**Code**”), we attach a copy of the announcement (the “**Announcement**”) released by Open Orphan plc (the “**Offeror**”) and the Company on 9 December 2019.

A summary of the disclosure requirements under Rule 8 of the Code for all persons with a direct or indirect interest of one per cent. or more of the issued ordinary share capital of the Company is set out below.

Yours faithfully,



Dr Trevor Nicholls
Senior Independent Director

hVIVO plc

Queen Mary BioEnterprises Innovation Centre | 42 New Road London E1 2AX United Kingdom | www.hvivo.com

Registered office - as shown above, registered in England and Wales | Company number: 08008725



Important notices

This document is for information purposes only. It does not constitute an offer or form part of any offer or an invitation to purchase, subscribe for, sell or issue any securities or a solicitation of any offer to purchase, subscribe for, sell or issue any securities pursuant to this document or otherwise in any jurisdiction in which such offer or solicitation is unlawful (a "Restricted Jurisdiction"). The distribution of this document in jurisdictions outside the United Kingdom may be restricted by law and therefore persons into whose possession this announcement comes should inform themselves about, and observe such restrictions. Any failure to comply with the restrictions may constitute a violation of the securities law of any such jurisdiction.

Disclosure requirements of the Code

Under Rule 8.3(a) of the Code, any person who is interested in 1% or more of any class of relevant securities of an offeree company or of any securities exchange offeror (being any offeror other than an offeror in respect of which it has been announced that its offer is, or is likely to be, solely in cash) must make an Opening Position Disclosure following the commencement of the offer period and, if later, following the announcement in which any securities exchange offeror is first identified. An Opening Position Disclosure must contain details of the person's interests and short positions in, and rights to subscribe for, any relevant securities of each of (i) the offeree company and (ii) any securities exchange offeror(s). An Opening Position Disclosure by a person to whom Rule 8.3(a) applies must be made by no later than 3.30 p.m. (London time) on the 10th business day following the commencement of the offer period and, if appropriate, by no later than 3.30 p.m. (London time) on the 10th business day following the announcement in which any securities exchange offeror is first identified. Relevant persons who deal in the relevant securities of the offeree company or of a securities exchange offeror prior to the deadline for making an Opening Position Disclosure must instead make a Dealing Disclosure.

Under Rule 8.3(b) of the Code, any person who is, or becomes, interested in 1% or more of any class of relevant securities of the offeree company or of any securities exchange offeror must make a Dealing Disclosure if the person deals in any relevant securities of the offeree company or of any securities exchange offeror. A Dealing Disclosure must contain details of the dealing concerned and of the person's interests and short positions in, and rights to subscribe for, any relevant securities of each of (i) the offeree company and (ii) any securities exchange offeror, save to the extent that these details have previously been disclosed under Rule 8. A Dealing Disclosure by a person to whom Rule 8.3(b) applies must be made by no later than 3.30 p.m. (London time) on the business day following the date of the relevant dealing.

If two or more persons act together pursuant to an agreement or understanding, whether formal or informal, to acquire or control an interest in relevant securities of an offeree company or a securities exchange offeror, they will be deemed to be a single person for the purpose of Rule 8.3.

Opening Position Disclosures must also be made by the offeree company and by any offeror and Dealing Disclosures must also be made by the offeree company, by any offeror and by any persons acting in concert with any of them (see Rules 8.1, 8.2 and 8.4).

Details of the offeree and offeror companies in respect of whose relevant securities Opening Position Disclosures and Dealing Disclosures must be made can be found in the Disclosure Table on the Takeover Panel's website at www.thetakeoverpanel.org.uk, including details of the number of relevant securities in issue, when the offer period commenced and when any offeror was first identified. You should contact the Panel's Market Surveillance Unit on +44 (0)20 7638 0129 if you are in any doubt as to whether you are required to make an Opening Position Disclosure or a Dealing Disclosure.

Electronic communications

hVIVO plc shareholders should note that addresses, electronic addresses and certain other information provided by them, persons with information rights and other relevant persons for the receipt of communications from the Company may be provided to Open Orphan plc during the Offer Period as required under section 4 of appendix 4 to the Code to comply with Rule 2.11(c) of the Code.

Publication on websites and availability of hard copies

Pursuant to Rule 26.1 of the Code, a copy of the Announcement and other documents in connection with the Offer will be available free of charge, subject to certain restrictions relating to persons resident in Restricted Jurisdictions, at Open Orphan plc's and hVIVO plc's websites at www.openorphan.com and www.hvivo.com respectively promptly after their publication and in any event by no later than 12 noon on the following business day until the end of the Offer Period (or, if later, the end of any competition reference period).

For the avoidance of doubt, the content of the websites referred to above is not incorporated into and does not form part of this document.

Copies of the Announcement and all future documents, announcements and information required to be sent to persons in relation to the Offer may be requested to be received by such persons in hard copy form by writing to Equiniti Limited at Corporate Actions, Aspect House, Spencer Road, Lancing BN99 6DA or by calling telephone number 0371 384 2050 (from within the UK) or +44 121 415 0259 (from outside the UK) between 8.30 a.m. and 5.30 p.m., Monday to Friday (excluding public holidays in England and Wales).

hVIVO plc contact details

hVIVO plc shareholders, persons with information rights and other relevant persons may contact Anesh Patel at hVIVO plc on telephone number 020 7148 1018 (or +44 20 7148 1018 from outside of the UK) between 9.00 a.m. and 5.00 p.m., Monday to Friday (other than UK public holidays) in respect of any administrative questions only they may have in relation to the matters contained in this document.

Definitions

Words and expressions defined in the Announcement shall, unless the context provides otherwise, have the same meanings in this document.

hVIVO plc

Queen Mary BioEnterprises Innovation Centre | 42 New Road London E1 2AX United Kingdom | www.hvivo.com

Registered office - as shown above, registered in England and Wales | Company number: 08008725